 |
|
|
|
Drug-Inducible Promoters hMDR1 and hLRP/MVP
Reference Number TO 03-00097
Promoter | inducible with: | induction rate | published | hMDR1 | Doxorubicin | 3 – 10 fold (in vitro) up to 25 fold (in vivo) | Gene Ther. 1997, 4: pp 544-552, see p 546 Cancer Gene Ther. 2000, 7:6, pp 893-900 | | Vincristin | 2,5 – 3fach (in vitro) in vivo | J Cancer Res. Clin. Oncol. 1996, 122: pp 275-282. Gene Ther. 1997, 4: pp 544-552, see p 548 | | Taxol | in vitro | Gene Ther. 1997, 4: pp 544-552, see p 548 | | Etoposid | in vitro | not yet published | | Hyperthermie (4143°C) | 2 – 7 fold (in vitro) up to 25 fold (in vivo) | Int. J. Cancer 2002, 98: pp 291-296 | | not inducible by 5-Fluorouracil | | Gene Ther. 1997, 4: pp 544-552, see p 548 | hLRP/MVP | 5-Fluorouracil | up to 3.5 fold | Oncogene, 2005, pp 1-13, see page 6 |
Commercial Opportunity
In-licensing, developing of research tool
Patent situation
I) MDR1 promoter-gene-construct: Priority 1992, granted patent in US, EP (validated in DE, FR, GB).
II) LRP/MVP promoter-gene-construct: Priority 2000, pending in US and EP
|
|
| |
|
|
